Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in diabetic metabolic dysfunction-associated steatotic liver disease management

doi:10.4239/wjd.119285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Jul 15, 2026; 17(7): 119285
Published online Jul 15, 2026. doi: 10.4239/wjd.119285

Open in New Tab Full Size Figure Download Figure

Figure 1 Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors on metabolic dysfunction-associated steatotic liver disease. MASLD: Metabolic dysfunction-associated steatotic liver disease; RCT: Randomized clinical trial; CVD: Cardiovascular disease; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.

Open in New Tab Full Size Figure Download Figure

Figure 2 Pharmacological effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors. MASLD: Metabolic dysfunction-associated steatotic liver disease; GLP-1RA: Glucagon-like peptide-1 receptor agonist; SGLT2: Sodium-glucose co-transporter 2.

Citation: Duman TT, Ucar Y, Turkoglu ES, Atak Tel BM, Bilgin S, Aktas G. Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in diabetic metabolic dysfunction-associated steatotic liver disease management. World J Diabetes 2026; 17(7): 119285
URL: https://www.wjgnet.com/1948-9358/full/v17/i7/119285.htm
DOI: https://dx.doi.org/10.4239/wjd.119285

Duman TT, Ucar Y, Turkoglu ES, Atak Tel BM, Bilgin S, Aktas G. Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in diabetic metabolic dysfunction-associated steatotic liver disease management. World J Diabetes 2026; 17(7): 119285 [DOI: 10.4239/wjd.119285]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.